PrismRA, a first of its kind molecular signature test, predicts non-response to TNFi therapies in patients with rheumatoid arthritis (RA) prior to prescribing target therapy.

Scipher’s new clinical utility study demonstrated that PrismRA reduces the ineffective use of TNFi therapies and increases therapeutic response across the RA population when utilized to inform medical decision-making.

Key takeaways from the study:

  • Predicted non-responders to TNFi therapies had significantly higher response rates to altMOAs than to TNFi 
  • TNFi response rates across the patient population were enriched by redirecting predicted non-responders to altMOAs 
  • Patients with and without a prediction of non-response showed comparable response rates to altMOAs, indicating PrismRA identifies true TNFi non-responders and not generally refractory patients

To read more on the study, please visit: